<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873027</url>
  </required_header>
  <id_info>
    <org_study_id>TRICVD1225</org_study_id>
    <secondary_id>UMIN000010580</secondary_id>
    <nct_id>NCT01873027</nct_id>
  </id_info>
  <brief_title>OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON</brief_title>
  <acronym>OPINION</acronym>
  <official_title>OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON (OPINION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized study is to evaluate the impact of Optical frequency domain
      imaging (OFDI) guidance for Percutaneous Coronay Intervention (PCI) with drug-eluting stent
      (DES) as compared with Intravascular ultrasound (IVUS) guidance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optical frequency domain imaging (OFDI) is a novel, high resolution intravascular imaging
      modality. Intravascular ultrasound (IVUS) is a widely used conventional imaging modality for
      achieving optimal stent deployment.

      The aim of this randomized study is to evaluate the impact of OFDI guidance for Percutaneous
      Coronay Intervention (PCI) with drug-eluting stent (DES) as compared with IVUS guidance.

      We will enroll 800 patients with a de novo lesion who will undergo PCI with DES as is routine
      practice. Patients will be rondomely assigned to either OFDI-guided PCI arm or IVUS-guided
      PCI arm.

      Patients will then have a follow-up contact at the time of hospital discharge, 8 month and 12
      month after PCI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 months after PCI</time_frame>
    <description>The composite endpoint comprised of cardiac death, target vessel-related myocardial infarction (MI) and clinically-driven target vessel revascularization (TVR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI)</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target lesion revascularization (TLR)</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (composite of cardiac death, MI, TLR)</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>12 months after PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>8 months after PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">829</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>OFDI-guided PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVUS-guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OFDI</intervention_name>
    <description>OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI</description>
    <arm_group_label>OFDI-guided PCI</arm_group_label>
    <other_name>LUNAWAVE</other_name>
    <other_name>Fastview</other_name>
    <other_name>Biolimus a9-eluting stent (Nobori stent)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IVUS</intervention_name>
    <description>IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI</description>
    <arm_group_label>IVUS-guided PCI</arm_group_label>
    <other_name>VISIWAVE</other_name>
    <other_name>ViewIT</other_name>
    <other_name>Biolimus A9-eluting stent (Nobori stent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a de novo lesion (in the native coronary circulation) and planned to
             undergo drug-eluting stent implantation for indications according to the Japan and USA
             guidelines

          -  Patients aged between 20 and 85 years old

          -  Patients who has provided written informed consent

        Exclusion Criteria:

          -  Patients with Acute Myocardial Infarction (AMI) within 3 months

          -  Patients with cardiogenic shock

          -  Patients with chronic heart failure

          -  Patients with renal failure (eGFR &lt;= 30 ml/min/1.73 m2 or Serum creatinine level
             &gt;=1.5mg/dL)

          -  Patients who are currently enrolled in other clinical trial which has possibility to
             influence the primary endpoint of OPINION trial.

          -  Patients planned use of bare metal stent

          -  Patients with 3-vessel diseases

          -  Planned surgery within 1 year

          -  Patient on dialysis

          -  Target lesion such as:

               -  Left main coronary artery

               -  Aorto-Ostial lesion location within 3mm of the aorta junction

               -  Chronic total occlusion

               -  Small vessel (reference vessel diameter &lt;2.5mm)

               -  Coronary artery bypass graft
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi Akasaka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wakayama Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <state>Wakayama Prefecture</state>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2013</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Optical Frequency Domain Imaging</keyword>
  <keyword>Intravascular Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Umirolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

